Home › Funds › Royalty Pharma Sub-Manager, LLC › KLRA

Royalty Pharma Sub-Manager, LLC position in KLRA

KAILERA THERAPEUTICS INC · Health Care

Royalty Pharma Sub-Manager, LLC reported holding 2,455,357 shares of KLRA (KAILERA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$28.0M, representing 14.29% of its reported portfolio and ranking #4 among its reported holdings. Royalty Pharma Sub-Manager, LLC has disclosed KLRA holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

Latest position (Q3 2026)2.46M sh
Reported value held$28.04M
Portfolio Weight14.29%
First reportedQ2 2026
Last changeHold
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Royalty Pharma Sub-Manager, LLC's KLRA position evolved

Royalty Pharma Sub-Manager, LLC first disclosed a stake in KLRA in Q2 2026 at 2,455,357 shares (US$54.1M). Across 2 filings, Royalty Pharma Sub-Manager, LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 2,455,357 shares valued at US$28.0M.

Quarter by quarter

QuarterSharesValueChange
Q2 2026 2.46M $54.09M New
Q3 2026 2.46M $28.04M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About KLRA and 13F data

KLRA (KAILERA THERAPEUTICS INC) is a Health Care company. 131 other funds we track also report a position in KLRA — the largest reported positions include BAIN CAPITAL INVESTORS LLC (US$578.4M), Bain Capital Life Sciences Investors, LLC (US$497.5M), RTW INVESTMENTS, LP (US$237.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding KLRA

All KLRA fund holders →

FAQ

How long has Royalty Pharma Sub-Manager, LLC held KLRA?

Royalty Pharma Sub-Manager, LLC has disclosed KLRA holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

What is Royalty Pharma Sub-Manager, LLC's current position in KLRA?

As of Q3 2026, Royalty Pharma Sub-Manager, LLC holds 2.46M shares of KLRA (KAILERA THERAPEUTICS INC), valued at $28.04M, representing 14.29% of its reported portfolio and ranking #4.

Has Royalty Pharma Sub-Manager, LLC been buying or selling KLRA?

In the latest 13F filing (Q3 2026), Royalty Pharma Sub-Manager, LLC held unchanged its position in KLRA.

Which other funds hold KLRA?

Other major institutional holders of KLRA include BAIN CAPITAL INVESTORS LLC, Bain Capital Life Sciences Investors, LLC, RTW INVESTMENTS, LP, among 131 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.